News
DBVT
0.7491
-2.30%
-0.0176
Weekly Report: what happened at DBVT last week (0318-0322)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Applied DNA Sciences (APDN) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. XTL Biopharmaceuticals (XTLB) shares increased by 19.31%. 2seventy bio (TSVT) shares rose 17.7%. Titan Pharma (TTNP) shares declined by 18.2% during the session.
Benzinga · 03/18 13:05
Weekly Report: what happened at DBVT last week (0311-0315)?
Weekly Report · 03/18 09:03
Weekly Report: what happened at DBVT last week (0304-0308)?
Weekly Report · 03/11 09:03
DBV Technologies Announces Completion of Annual Report
TipRanks · 03/08 21:24
Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes
TipRanks · 03/08 11:29
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Barchart · 03/08 08:33
EUROPE RESEARCH ROUNDUP-Aena SME SA, Arkema SA, ITV Plc
Analysts revise ratings and price targets on several European companies. Aena SME SA, Arkema SA, ITV Plc and ITV raise their targets. HSBC cuts target price to EUR 107 from EUR 111 for ITV. A.G. Barr raises to equal weight from underweight.
Reuters · 03/08 07:03
Positive Clinical and Financial Projections for DBV Technologies Reinforce Buy Rating
TipRanks · 03/08 05:26
DBV Technologies Q4 2023 GAAP EPS $(0.060), Sales $8.875M Beat $412.000K Estimate
Benzinga · 03/07 22:31
DBV Technologies GAAP EPS of -$0.76, revenue of $15.7M
Seeking Alpha · 03/07 22:18
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
DBV Technologies Reports Full Year 2023 Financial Results and Business Update. DBV is a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need. The audit procedures for the full year 2023 have been completed.
Barchart · 03/07 15:30
Earnings Scheduled For March 7, 2024
CI&T is expected to report quarterly earnings at $0.06 per share on revenue of $106.08 million. Other companies expected to release earnings before the bell include Burlington Stores, American Eagle Outfitters and Bilibili. The companies will also be reporting earnings for their third quarter.
Benzinga · 03/07 09:49
A Preview Of DBV Technologies's Earnings
DBV Technologies is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Analysts estimate the company will report an earnings per share of $-0.25. Shares of DBV Technologies were trading at $0.8449 as of March 05.
Benzinga · 03/06 17:01
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024. The Company will host a conference call and live audio webcast to review full year 2023 financial results and provide a business update. DBV Technologies is a clinical-stage biopharmaceutical company focused on treatments for food allergies.
Barchart · 03/04 15:30
Weekly Report: what happened at DBVT last week (0226-0301)?
Weekly Report · 03/04 09:03
Weekly Report: what happened at DBVT last week (0219-0223)?
Weekly Report · 02/26 09:03
Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials
TipRanks · 02/26 05:25
DBV Technologies Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 02/21 11:57
HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $10 Price Target
Benzinga · 02/21 11:47
More
Webull provides a variety of real-time DBVT stock news. You can receive the latest news about Dbv Technologies S A through multiple platforms. This information may help you make smarter investment decisions.
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.